11/24/20 7:00 AMNYSE : BHCBausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland DysfunctionBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the investigationalRHEA-AIneutral
11/18/20 4:51 PMNYSE : BHCBausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior NotesBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1.0 billionRHEA-AIneutral
11/18/20 7:08 AMNYSE : BHCBausch Health Announces Launch Of Private Offering Of Senior Notes And Conditional Redemption Of Existing Senior NotesBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined $1.75 billion aggregate principal amount of new senior notes due 2029 (the "2029 Notes") and new senior notes dueRHEA-AIneutral
11/16/20 7:00 AMNYSE : BHCBausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY(R) And BESIVANCE(R) Eye Drops Preserved With Benzalkonium ChlorideBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, today announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved eye drops,RHEA-AInegative
11/12/20 6:59 AMNYSE : BHCBausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling ProgramBausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blisterRHEA-AIneutral
11/11/20 7:00 AMNYSE : BHCSalix To Present Data At AASLD's The Liver Meeting Digital ExperienceBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment ofRHEA-AIneutral
11/10/20 7:00 AMNYSE : BHCBausch Health Announces Participation In Upcoming Investor ConferencesBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in two investor conferences.Joseph C. Papa, chairman and chief executive officer, Sam Eldessouky, senior vice president andRHEA-AIneutral
11/03/20 6:59 AMNYSE : BHCBausch Health Companies Inc. Announces Third-Quarter 2020 ResultsThird-Quarter 2020 Financial ResultsRevenues of $2.138 BillionGAAP Net Income of $71 MillionAdjusted EBITDA (non-GAAP)1of $948 MillionGAAP Cash Generated from Operations of $256 MillionReaffirmed 2020 Full-Year Revenue and Adjusted EBITDARHEA-AIneutral
10/29/20 4:05 PMNYSE : BHCBausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell DiseaseBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment ofRHEA-AIneutral
10/29/20 7:00 AMNYSE : BHCBausch Health To Reduce Debt By $150 Million Using Cash Generated From OperationsBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on Nov. 30, 2020 it will redeem (i) approximately $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023, CUSIP Nos.RHEA-AIneutral
